AN2 Therapeutics Q3 2026 net loss narrows 15% to $7.96 million

PUBT · 11/09 12:31
AN2 Therapeutics Q3 2026 net loss narrows 15% to $7.96 million
  • AN2 Therapeutics’ third-quarter 2026 net loss narrowed 15% year-over-year to $7.96 million.
  • Research and development expenses fell 18% year-over-year to $5.72 million.
  • Cash, cash equivalents and investments totaled $80.2 million at September 30, 2026, with projected funding into 2029.
  • The global Phase 2 epetraborole study in polycythemia vera secured all planned regulatory clearances; enrollment is expected by year-end 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261109907823) on November 09, 2026, and is solely responsible for the information contained therein.